Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 2,950 $ 16,522
Note receivable - LINICO 250 600
Accounts receivable 486 67
Inventory 330 929
Prepaid expenses and other current assets 148 181
Total current assets 4,164 18,299
Non-current assets    
Property, plant and equipment, net 16,615 10,347
Intellectual property, net 164 281
Other assets 7,540 4,673
Total non-current assets 24,319 15,301
Total assets 28,483 33,600
Current liabilities    
Accounts payable 1,477 1,836
Accrued Expenses 2,314 2,467
Lease liability, current portion 286 275
Note payable, current portion 2,988 35
Total current liabilities 7,065 4,613
Lease liability, non-current portion 520 0
Note payable, non-current portion 0 2,923
Total liabilities 7,585 7,536
Commitments and contingencies (see Note 12)
Stockholders’ equity    
Common stock; $0.001 par value; 300,000,000 shares authorized; 6,855,991 and 6,826,572, shares issued and outstanding as of September 30, 2024, respectively and 5,415,433 and 5,394,005 shares issued and outstanding as of December 31, 2023, respectively 7 5
Additional paid-in capital 261,410 249,790
Accumulated deficit (240,327) (223,215)
Treasury stock, at cost; common shares: 29,419 and 21,428 as of September 30, 2024 and December 31, 2023, respectively (192) (516)
Total stockholders’ equity 20,898 26,064
Total liabilities and stockholders’ equity $ 28,483 $ 33,600